A Targeted Electronic Health Approach to Reduce Fear of Recurrence in Breast Cancer Survivors (FoRtitude)

NCT ID: NCT07122492

Last Updated: 2025-08-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

800 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-09-01

Study Completion Date

2029-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this study is to determine if the intervention or if general information about being a breast cancer survivor can help Breast Cancer Survivors reduce their fear of recurrence. The main question it aims to answer are:

Can the FoRtitude intervention lower the fear of recurrence for Breast Cancer Survivors?

Participants will:

Answer questions about their fear of recurrence. Be randomized to 1 of the 3 following options: (1) a weblink to access an eHealth intervention which includes a website and an optional interactive text-messaging feature, (2) a weblink to a non-interactive website that will include links to external websites with general information that may be helpful for Breast Cancer Survivors, or (3) you will need to talk with your oncology team about your concerns about recurrence or seek psychosocial care in the community.

Be asked to fill out questionnaires 5 times for up to 18 months.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer Survivor Fear of Cancer Recurrence

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention

Access to the study intervention website with interactive content, including information to read and videos to watch, and an optional text-messaging feature

Group Type EXPERIMENTAL

FoRtitude 2.0

Intervention Type BEHAVIORAL

A website and an interactive text-messaging feature

Attentive Care

Access to the non-interactive study intervention website that lists links to help you access websites that provide information to read and resources for breast cancer survivors.

Group Type OTHER

Attention Control

Intervention Type BEHAVIORAL

Access to the non-interactive study intervention website that lists links to help you access websites that provide information to read and resources for breast cancer survivors.

Usual Care

Usual care for fear of recurrence.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

FoRtitude 2.0

A website and an interactive text-messaging feature

Intervention Type BEHAVIORAL

Attention Control

Access to the non-interactive study intervention website that lists links to help you access websites that provide information to read and resources for breast cancer survivors.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participant must be ≥ 18 years of age.
* Participant must have had histologically confirmed Stage 0-III breast cancer at time of diagnosis.
* Participant must have completed primary treatment 1-10 years prior to Step 0 registration.

NOTE: Current hormonal therapy is allowed. NOTE: Primary treatment can include chemotherapy and/or surgery and/or radiation therapy.

\- Participant must be receiving their care (cancer treatment or survivorship care) from an oncology provider affiliated with the NCORP site and are expected to continue care at the site for the next 18 months.

NOTE: This eligibility criteria is intended to ensure access to healthcare utilization data. Oncology provider can include an Advance Practice Provider, Advance Nurse Practitioner, oncologist, primary care provider, or nurse or physician responsible for survivorship care.

* Participant must have no evidence of active cancer of any type at the time of Step 0 registration (per the assessment of the physician), excluding local basal cell or squamous cell carcinoma.
* Participant must be fluent in written and spoken English.
* Participant must have an ECOG Performance Status of 0-2.
* Participant must have the ability to understand and the willingness to sign a written informed consent document. Participants with impaired decision-making capacity (IDMC) are not eligible.
* Participant must complete the FCRI 9-item severity scale and report a score of 13 or higher.
* Participant must have access to the internet (via smartphone, tablet, or computer).

NOTE: The restriction to those with internet access is based on the primary intention of the study which involves internet-based delivery intervention content delivered via the internet.

* Participant must have completed the Baseline Assessment within 60 days of Step 0 registration.
* Randomization to Step 1 must occur within 60 days of Step 0 registration.

Exclusion Criteria

* Participant must not have any psychiatric or cognitive conditions that may affect the participant's ability to accurately provide self-report data, per clinical discretion.
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Eastern Cooperative Oncology Group

NETWORK

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Lynne I Wagner, Ph.D.

Role: STUDY_CHAIR

UNC Chapel Hill Gillings School of Global Public Health

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

UNC Chapel Hill School of Medicine Public Health

Chapel Hill, North Carolina, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Lynne I Wagner, Ph.D.

Role: CONTACT

(919) 966-7392

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Lynne I Wagner, Ph.D.

Role: primary

(919) 966-7392

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EAQ181

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Time Restricted Eating in Survivors Trial 2.0
NCT07259434 NOT_YET_RECRUITING NA